151 related articles for article (PubMed ID: 32997825)
1. VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
Kaddu-Mulindwa D; Rosolowski M; Ziepert M; Regitz E; Assmann G; Bewarder M; Held G; Pfreundschuh M; Bittenbring JT
Eur J Haematol; 2021 Jan; 106(1):100-104. PubMed ID: 32997825
[TBL] [Abstract][Full Text] [Related]
2. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
Kim MK; Suh C; Chi HS; Cho HS; Bae YK; Lee KH; Lee GW; Kim IS; Eom HS; Kong SY; Bae SH; Ryoo HM; Shin IH; Mun YC; Chung H; Hyun MS
Cancer Sci; 2012 Mar; 103(3):497-503. PubMed ID: 22129133
[TBL] [Abstract][Full Text] [Related]
3. Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Yoon KA; Kim MK; Eom HS; Lee H; Park WS; Sohn JY; Kim MJ; Kong SY
Leuk Lymphoma; 2017 Nov; 58(11):2677-2682. PubMed ID: 28326867
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
Kim DH; Xu W; Kamel-Reid S; Liu X; Jung CW; Kim S; Lipton JH
Ann Oncol; 2010 Jun; 21(6):1179-1188. PubMed ID: 19875757
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia.
Góra-Tybor J; Szemraj J; Robak T; Jamroziak K
Blood Cells Mol Dis; 2015 Feb; 54(2):139-43. PubMed ID: 25488616
[TBL] [Abstract][Full Text] [Related]
6. Association of Genetic Polymorphisms on VEGFA and VEGFR2 With Risk of Coronary Heart Disease.
Liu D; Song J; Ji X; Liu Z; Cong M; Hu B
Medicine (Baltimore); 2016 May; 95(19):e3413. PubMed ID: 27175642
[TBL] [Abstract][Full Text] [Related]
7. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).
Gratzinger D; Advani R; Zhao S; Talreja N; Tibshirani RJ; Shyam R; Horning S; Sehn LH; Farinha P; Briones J; Lossos IS; Gascoyne RD; Natkunam Y
Br J Haematol; 2010 Jan; 148(2):235-44. PubMed ID: 19821819
[TBL] [Abstract][Full Text] [Related]
8. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
9. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
Brito ABC; Delamain MT; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Lima CSP
Tumour Biol; 2021; 43(1):129-140. PubMed ID: 34219681
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
[TBL] [Abstract][Full Text] [Related]
12. Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study.
Zhang J; Yang J; Chen Y; Mao Q; Li S; Xiong W; Lin Y; Chen J; Ge J
Mol Neurobiol; 2016 May; 53(4):2610-8. PubMed ID: 26093379
[TBL] [Abstract][Full Text] [Related]
13. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Hüttmann A; Rekowski J; Müller SP; Hertenstein B; Franzius C; Mesters R; Weckesser M; Kroschinsky F; Kotzerke J; Ganser A; Bengel FM; La Rosée P; Freesmeyer M; Höffkes HG; Hertel A; Behringer D; Prange-Krex G; Griesshammer M; Holzinger J; Wilop S; Krohn T; Raghavachar A; Maschmeyer G; Brink I; Schroers R; Gaska T; Bernhard H; Giagounidis A; Schütte J; Dienst A; Hautzel H; Naumann R; Klein A; Hahn D; Pöpperl G; Grube M; Marienhagen J; Schwarzer A; Kurch L; Höhler T; Steiniger H; Nückel H; Südhoff T; Römer W; Brinkmann M; Ose C; Alashkar F; Schmitz C; Dürig J; Hoelzer D; Jöckel KH; Klapper W; Dührsen U
Ann Hematol; 2019 Apr; 98(4):897-907. PubMed ID: 30610279
[TBL] [Abstract][Full Text] [Related]
14. Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
Hohloch K; Altmann B; Pfreundschuh M; Loeffler M; Schmitz N; Zettl F; Ziepert M; Trümper L
Br J Haematol; 2018 Jan; 180(2):236-245. PubMed ID: 29193018
[TBL] [Abstract][Full Text] [Related]
15. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
16. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.
Ahlgrimm M; Pfreundschuh M; Kreuz M; Regitz E; Preuss KD; Bittenbring J
Blood; 2011 Oct; 118(17):4657-62. PubMed ID: 21900198
[TBL] [Abstract][Full Text] [Related]
17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
18. The Effect of FcγRIIIA Gene Polymorphism on the Treatment of Diffuse Large B-cell Non-Hodgkin Lymphoma: A Multicenter Prospective Observational Study.
Büyükkurt N; Özcan MA; Ergene Ü; Payzın B; Tunalı S; Demirkan F; Özsan H; Pişkin Ö; Ündar B
Turk J Haematol; 2015 Jun; 32(2):152-7. PubMed ID: 26316483
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
